Compass Therapeutics, Inc. (NASDAQ:CMPX) Short Interest Update

Compass Therapeutics, Inc. (NASDAQ:CMPX) saw a large decrease in short interest in January. As of January 31st, there was short interest totalling 2,750,000 shares, a decrease of 13.8% from the January 15th total of 3,190,000 shares. Based on an average daily volume of 1,280,000 shares, the short-interest ratio is presently 2.1 days. Currently, 3.3% of the company’s stock are short sold.

Compass Therapeutics Stock Performance

Shares of NASDAQ CMPX opened at $3.38 on Tuesday. Compass Therapeutics has a 52-week low of $0.76 and a 52-week high of $4.08. The firm has a 50 day moving average price of $2.31 and a two-hundred day moving average price of $1.83. The stock has a market cap of $465.05 million, a P/E ratio of -9.13 and a beta of 1.17.

Institutional Investors Weigh In On Compass Therapeutics

Institutional investors have recently modified their holdings of the company. Enavate Sciences GP LLC bought a new position in Compass Therapeutics during the fourth quarter worth $11,293,000. Tang Capital Management LLC raised its holdings in shares of Compass Therapeutics by 225.4% in the fourth quarter. Tang Capital Management LLC now owns 5,900,000 shares of the company’s stock valued at $8,555,000 after purchasing an additional 4,087,005 shares during the last quarter. MPM Bioimpact LLC increased its holdings in Compass Therapeutics by 51.9% during the fourth quarter. MPM Bioimpact LLC now owns 8,567,896 shares of the company’s stock worth $12,423,000 after buying an additional 2,926,002 shares during the last quarter. SG Americas Securities LLC increased its holdings in Compass Therapeutics by 921.6% during the fourth quarter. SG Americas Securities LLC now owns 395,017 shares of the company’s stock worth $573,000 after buying an additional 356,352 shares during the last quarter. Finally, JPMorgan Chase & Co. increased its holdings in Compass Therapeutics by 512.5% during the fourth quarter. JPMorgan Chase & Co. now owns 272,328 shares of the company’s stock worth $395,000 after buying an additional 227,864 shares during the last quarter. 68.43% of the stock is owned by institutional investors.

Analysts Set New Price Targets

A number of equities research analysts have recently issued reports on the company. HC Wainwright reiterated a “buy” rating and set a $10.00 price objective on shares of Compass Therapeutics in a research note on Wednesday, January 8th. D. Boral Capital reiterated a “buy” rating and set a $32.00 price objective on shares of Compass Therapeutics in a research report on Wednesday, January 8th. Leerink Partners cut Compass Therapeutics from an “outperform” rating to a “market perform” rating and decreased their price target for the stock from $5.00 to $4.00 in a research report on Friday, November 15th. Leerink Partnrs cut shares of Compass Therapeutics from a “strong-buy” rating to a “hold” rating in a research report on Friday, November 15th. Finally, Jefferies Financial Group boosted their target price on shares of Compass Therapeutics from $7.00 to $8.00 and gave the company a “buy” rating in a research report on Monday, February 10th. Two analysts have rated the stock with a hold rating and five have issued a buy rating to the company’s stock. According to data from MarketBeat, Compass Therapeutics presently has a consensus rating of “Moderate Buy” and a consensus price target of $11.17.

About Compass Therapeutics

Compass Therapeutics, Inc, a clinical-stage oncology-focused biopharmaceutical company, engages in developing antibody-based therapeutics to treat various human diseases in the United States. The company's lead product candidates include CTX-009, a bispecific antibody that blocks Delta-like ligand 4 a ligand of Notch-1, and vascular endothelial growth factor A signaling pathways, which are critical to angiogenesis and tumor vascularization; and CTX-471, an IgG4 monoclonal antibody that is an agonist of CD137, a key co-stimulatory receptor on immune cells.